30 July 2018
Visiongain’ has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico
The generic drugs market has historically increased at near double-digit growth rates over the last three decades, compared to single-digit growth for the pharmaceutical market as a whole. The industry has benefited from increasing generic penetration in most major markets notable exceptions being Japan, France, Italy and Spain, where generic penetration is increasing slowly. This trend is likely to continue as falling R&D productivity begins to limit revenues for innovator companies while cost pressures encourage the growth of generic sales by volume.
The lead analyst of the report commented “The socio-economic landscape of many national and regional markets globally has been changing immensely over the last decade. This factor, coupled with the changing in the demographics of these regions will help to shape the future direction of generic drugs over the next 10 years. Population growth and ageing are expected to increase the burden of disease, especially chronic diseases such as diabetes and hypertension. This will be a major driver of the demand for generic medicines during the forecast period.”
Leading companies featured in the report include Teva, Novartis (Sandoz), Allergan, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories, Apotex
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 208 781 6953
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.